PolyMedix, Inc.
170 North Radnor Chester Road
Suite 300
Radnor,
PA 19087
United States - Map
Phone: 484-598-2400
Fax: 484-598-2401
Web Site: http://www.polymedix.com
| PolyMedix, Inc., a development stage biotechnology company, focuses on treating infectious diseases and acute cardiovascular disorders with synthetic small molecule compounds that mimic the activity of natural protein molecules. The companys product candidates that have completed Phase 1A clinical trials include PMX-30063, a defensin mimetic i.v. antibiotic; and PMX-60056Heptagonist, an unfractionated heparin and low molecular weight heparins reversing agent. Its pre-clinical stage compounds include PMX-30063, a defensin mimetic ophthalmic antibiotic for the treatment of eye infections; PMX-70004 and PMX-50003 that are defensin mimetic polymer biomaterials; PMX-30063, a defensin mimetic oral antibiotic for the treatment of gastrointestinal infections, such as Clostridium difficile; PMX-10070, a defensin mimetic anti-tuberculosis compound; PMX-70008 and PMX-30024 that are defensin anti-malaria compounds; PMX-10098, a defensin mimetic anti-fungal/viral compound; and PMX-20005, an angiogenesis inhibitor for the treatment of cancer. The company was founded in 2002 and is based in Radnor, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Frank P. Slattery Jr., 71
Chairman, Member of Audit Committee, Member of Nominating & Corp. Governance Committee and Co-founder of PolyMedix Pharmaceuticals Inc |
$
29.00K | N/A | Mr. Nicholas Landekic , 50
Chief Exec. Officer, Pres and Exec. Director |
N/A
| N/A | Mr. Edward F. Smith , 38
Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Sec. |
$
281.00K | N/A | Dr. R. Eric McAllister M.D., D.Phil. (Ph.D.), 67
Chief Medical Officer and VP of Clinical Devel. |
$
343.00K | N/A | Dr. Richard W. Scott Ph.D., 56
VP of Research |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 0.00%
Profile
